AI Summary

NIH researchers identified rare monoclonal antibodies that can block human allergic antibodies from binding to red‑meat allergens linked to alpha‑gal syndrome (AGS), an emerging tick‑bite condition. Laboratory tests showed the antibodies act as a biological shield, preventing the allergic reaction to the alpha‑gal molecule found in non‑primate mammal products. The discovery, reported in the Journal of Clinical Investigation, is described by NIH’s acting NIAID director as the first step toward potential prevention strategies and targeted therapies for AGS, which currently has no specific treatment beyond avoiding red meat.

AI summaries can be wrong sometimes—always verify important details using the source article.